Treatment for Acute Ischaemic Stroke

Cardiovascular

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heart beats (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).


Acute ischaemic stroke, the most common type of stroke, occurs when the blood supply to part of the brain is blocked by either a blood clot in a brain vessel or atherosclerosis (fatty deposits or plaques lining vessel walls). A stroke can lead to disability or even death and always requires quick, acute treatment. Boehringer Ingelheim led the way in stroke care by developing the only licensed blood clot dissolving treatment (thrombolytic) for acute ischaemic stroke therapy, which is now used in stroke centres worldwide.

Boehringer Ingelheim also sponsors the angels initiative: a programme that helps doctors to set up and optimise acute stroke networks with the support of local and international stroke societies.

Information for...
General Use Patients or Carers Health Care Professionals in the US Health Care Professionals outside the US and UK Journalists Jobseekers